Javascript er ikke aktivert i din nettleser. Dette er nødvendig for å bruke Oncolex. Kontakt din systemadministrator for å aktivere JavaScript.

Prognosis of neuroendocrine tumors

At Oslo University Hospital (Rikshospitalet), the registered patients with:

  • intestinal tumors have a 5 year survival rate of 88% with local disease at the time of diagnosis
  • pancreatic tumors have a 5 year survival rate of 57%
  • metastasis at the time of diagnosis have a 5 year survival rate of 64% (intestinal tumors) and 42% (pancreatic tumors)

The tumor is often so advanced at the time of diagnosis that radical surgery is not possible.

Based on the SEERS database from the US, survival varies with differential degrees and with primary focus. The 5 year survival in highly differentiated tumors, with distant metastases, from the intestines is 54%, coecum 48%, followed by lungs 27%, pancreas 27%, and appendix 25%.

Few patients with poorly differentiated carcinomas that is not radically resected are a live one year after diagnosis.


Oslo University Hospital shall not be liable for any loss whether direct, indirect, incidental or consequential, arising out of access to, use of, or reliance upon any of the content on this website. Oslo University Hospital© 2018